Health status of Asian Americans

Huawei's Barcelona Launch event: A New Era of Stylish, Health-Focused, and Sport-Ready Wearables

Retrieved on: 
Thursday, September 14, 2023

Huawei's Ambition to Elevate Design, Health and Sport Experience

Key Points: 
  • Huawei's Ambition to Elevate Design, Health and Sport Experience
    Huawei aims to empower users to personalise their health and sports journey without compromising style.
  • Drawing from a decade of expertise in innovative technology, unique aesthetics, and premium craftsmanship, Huawei is setting new industry benchmarks.
  • Huawei's presence in the high-end wearables market internationally, and forge global ecosystem partnerships to deliver personalized sports and healthy lifestyle experiences to consumers worldwide.
  • With pioneering features such as HUAWEI TruSportTM science-based system, Huawei has turned wearables into personal coach right on your wrist.

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Retrieved on: 
Saturday, September 16, 2023

You’ve six months to work on your diet to see if that’ll bring down your levels, then you’ll review your options.

Key Points: 
  • You’ve six months to work on your diet to see if that’ll bring down your levels, then you’ll review your options.
  • But there’s some good evidence that taking particular supplements, while also eating a healthy diet, can make a difference.

Why are we so worried about cholesterol?

    • Low-density lipoprotein or LDL cholesterol This is often called “bad” cholesterol.
    • This lipoprotein helps remove excess cholesterol from the bloodstream and transports it back to the liver for processing and excretion.
    • Diet can play a key role in reducing blood cholesterol levels, especially LDL (“bad”) cholesterol.

Fibre is your friend

    • An additional way to significantly reduce your total cholesterol and LDL cholesterol levels through diet is by eating more soluble fibre.
    • This is a type of fibre that dissolves in water to form a gel-like substance in your gut.

Fibre supplements, such as psyllium


    There are also many fibre supplements and food-based products on the market that may help lower cholesterol. These include:
    • Psyllium is the fibre supplement with the strongest evidence to support its use in improving cholesterol levels.
    • These trials show consuming about 10g of psyllium a day (1 tablespoon), as part of a healthy diet, can significantly lower total cholesterol levels by 4% and LDL cholesterol levels by 7%.

Probiotics

    • Probiotics are thought to help lower cholesterol levels via a number of mechanisms.
    • Using probiotics to reduce cholesterol is an upcoming area of interest and the research is promising.
    • Most of these studies use probiotics containing Lactobacillus acidophilus and Bifidobacterium lactis, which come in capsules or powders and are consumed daily.

Red yeast rice

    • Red yeast rice is another non-fibre supplement that has gained attention for lowering cholesterol.
    • It found taking red yeast rice supplements (200-4,800mg a day) was more effective for lowering blood fats known as triglycerides but less effective at lowering total cholesterol compared with statins.
    • However, these trials don’t tell us if red yeast rice works and is safe in the long term.

Diet and supplements may not be enough

    • Always speak to your GP and dietitian about your plan to take supplements to lower your cholesterol.
    • But remember, dietary changes alone – with or without supplements – might not be enough to lower your cholesterol levels sufficiently.
    • Even then, depending on your cholesterol levels and other risk factors, you may still be recommended cholesterol-lowering medications, such as statins.

United States Diagnostics Market Research Report 2023-2031: Diagnostics and the Key Role in Enabling Identification, Monitoring, and Management - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 14, 2023

The "United States Diagnostics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Diagnostics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The United States diagnostics market is poised for substantial expansion, projected to achieve a Compound Annual Growth Rate (CAGR) of 5.17% between 2023 and 2031.
  • It encompasses an extensive spectrum of products and services, encompassing diagnostic tests, laboratory equipment, imaging systems, and molecular diagnostics.
  • Diagnostics hold a pivotal role in healthcare, functioning as indispensable tools for identifying, monitoring, and managing various diseases and conditions.

Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Retrieved on: 
Wednesday, September 13, 2023

The CRDAC voted 9:3 that the benefits of patisiran outweigh its risks for the treatment of the cardiomyopathy of ATTR amyloidosis.

Key Points: 
  • The CRDAC voted 9:3 that the benefits of patisiran outweigh its risks for the treatment of the cardiomyopathy of ATTR amyloidosis.
  • The CRDAC’s vote, while not binding, will be considered by the FDA when making its decision regarding the potential expanded indication for patisiran.
  • Patisiran is the established name for ONPATTRO®, which is approved by the FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.
  • Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Blue Shield of California and Salesforce Advance Holistic Care Management and Enable Streamlined Employer Enrollment, Improving Time to Care

Retrieved on: 
Wednesday, September 13, 2023

OAKLAND, Calif. and SAN FRANCISCO, Sept. 13, 2023 /PRNewswire/ -- Blue Shield of California and Salesforce (NYSE: CRM), the #1 AI CRM, today announced an expanded collaboration to meet members' need for unified experiences by leveraging the agility and breadth of the Salesforce platform. With its adoption of Salesforce Health Cloud, Blue Shield of California will be able to expand and scale more in-depth care management services to its members, promoting higher quality care. Additionally with Salesforce, Blue Shield is bringing together a consistent enrollment experience for employers and brokers to reduce the processing time for benefits administration from 24 hours to just five minutes.

Key Points: 
  • With its adoption of Salesforce Health Cloud , Blue Shield of California will be able to expand and scale more in-depth care management services to its members, promoting higher quality care.
  • To gain a unified view of the health status of its members, Blue Shield of California and Salesforce created Care Connect, a clinical care management system built on Salesforce Health Cloud.
  • Supporting Blue Shield in transforming the future of care in California represents a core focus and commitment for our team."
  • The scalable solution will help Blue Shield expand self-service capabilities and quickly adapt to ever-evolving market needs for care and services.

The Balm In Gilead Presents Prostate Cancer and Black Men Live Webinar

Retrieved on: 
Tuesday, September 12, 2023

RICHMOND, Va., Sept. 12, 2023 /PRNewswire/ -- In efforts to drive awareness about health disparities in the United States that result in higher rates of prostate cancer diagnosis and death for Black men, The Balm In Gilead, Inc., a national non-profit organization, will present a free webinar titled "Talk That Talk: Prostate Cancer and Black Men" on September 12, 2023  at 7:00pmET via Zoom. Registration is required.

Key Points: 
  • RICHMOND, Va., Sept. 12, 2023 /PRNewswire/ -- In efforts to drive awareness about health disparities in the United States that result in higher rates of prostate cancer diagnosis and death for Black men, The Balm In Gilead, Inc., a national non-profit organization, will present a free webinar titled "Talk That Talk: Prostate Cancer and Black Men" on September 12, 2023 at 7:00pmET via Zoom .
  • "Because one in six Black men will be diagnosed with prostate cancer, our webinar will examine gaps in awareness and knowledge that contribute to delays in Black men seeking screening and treatment for this disease," said Pernessa C. Seele, Ph.D., founder and CEO of The Balm In Gilead, Inc.
    Dr. Seele will host the webinar, which features an esteemed panel moderated by Rev.
  • Dr. Nathaniel T. Brooks, senior pastor, Greater St. John Baptist Church, Birmingham, AL,  who is a leader in community cancer education.
  • The "Talk That Talk" webinar is presented with support from the Janssen Pharmaceutical Companies of Johnson & Johnson's Talk That Talk™, an educational campaign and call to action to drive prostate cancer awareness and reinforce the importance of screening for early detection among Black men.

SenseAuto Debuts in Europe at IAA Mobility 2023 Driving the Future of Smart Mobility with Cutting-Edge AGI

Retrieved on: 
Wednesday, September 6, 2023

MUNICH, Sept. 6, 2023 /PRNewswire/ -- SenseAuto, a leading global provider of artificial general intelligence (AGI) technology for the smart auto era, is showcasing its industry-first and AGI-powered solutions for smart mobility at IAA Mobility 2023, held in Munich, Germany from September 5-10, 2023.

Key Points: 
  • MUNICH, Sept. 6, 2023 /PRNewswire/ -- SenseAuto, a leading global provider of artificial general intelligence (AGI) technology for the smart auto era, is showcasing its industry-first and AGI-powered solutions for smart mobility at IAA Mobility 2023, held in Munich, Germany from September 5-10, 2023.
  • As a global frontrunner of smart technology for the automotive industry, SenseAuto is leading the way with its full-stack AGI capabilities that empowers the next generation of mobility.
  • Prof. Wang Xiaogang, Co-founder and CEO of SenseAuto, delivered a keynote speech at the conference today titled "Empowering Intelligent Vehicles with Artificial General Intelligence".
  • "We are excited to join this year's IAA Mobility where we are showcasing our innovations and the future we envision for smart mobility," said Prof. Wang Xiaogang.

Revolutionizing Pet Care: The World's First Automatic Litter Refilling Smart Litter Box - LALAHOME Real Scooper

Retrieved on: 
Tuesday, August 29, 2023

ANAHEIM, Calif., Aug. 29, 2023 /PRNewswire/ -- Through Indiegogo's prelude, the much-anticipated revolutionary leap in the pet industry comes to light. LALAHOME Real Scooper, the world's first smart cat litter box capable of self-refilling and odor control.

Key Points: 
  • LALAHOME Real Scooper, the world's first smart cat litter box capable of self-refilling and odor control.
  • Unlike current smart litter boxes that fail to automatically replenish litter, leading to deteriorating litter conditions that cats refuse to use.
  • The debut of LALAHOME Real Scooper introduces a brand-new experience for pet owners, creating a cleaner and more comfortable living environment for cats.
  • Join the revolution now and make the Real Scooper the best companion for all cat owners and their beloved cats.

LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology

Retrieved on: 
Monday, August 28, 2023

Mavacamten also demonstrated improvement across all secondary endpoints, including LVOT obstruction, clinical symptoms, and health status.

Key Points: 
  • Mavacamten also demonstrated improvement across all secondary endpoints, including LVOT obstruction, clinical symptoms, and health status.
  • The data presented at ESC 2023 and published in JAMA Cardiology continue to demonstrate robust evidence of mavacamten’s therapeutic benefit.
  • As previously reported, safety results in the trial were consistent with previous studies of mavacamten in symptomatic oHCM, and no new safety signals were reported.
  • “The EXPLORER-CN trial demonstrates that the well-established therapeutic benefit of this drug also extends to Chinese patients.

Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

Retrieved on: 
Monday, August 28, 2023

Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
  • Overall, 75.9% of patients improved by ≥1 NYHA class from baseline at the start of the LTE study to Week 120.
  • Of the 14 patients who were in NYHA class I, 12 remained in NYHA class I at the latest available assessment.
  • “Studies like EXPLORER-LTE are important for understanding longer-term results that assess key cardiac measures and support the use of CAMZYOS in patients living with this chronic condition.”